EUVIMEDEUVIMED entdecken
Crossref

Discovery of rigid linker-based CDK4/6 PROTACs for the treatment of breast cancer

Guoyong Pan, You Li, Jinke Tan, Yuanyuan Chen, Weijiao Chen, Huanaoyu Yang, Xujie Zhuang, Linhu Shen, Ziyu Zong, Yiming Fan, Jiadong Gao, Liping Wang und 3 weitere

Bioorganic Chemistry · 2026

DOI: 10.1016/j.bioorg.2026.110368 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Guoyong Pan und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines and Jiangsu Provincial Key Laboratory of Targetome and innovative Drugs Medicines, China Pharmaceutical Uni…. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4, Breast Neoplasms, Antineoplastic Agents. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, Jiangsu Province Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Selective cyclin-dependent kinase (CDK) 4/6 inhibitors play a leading role in the treatment of breast cancer; however, their efficacy is often limited by acquired resistance. Proteolysis-targeting chimera (PROTAC) technology has recently emerged as a promising therapeutic strategy to overcome drug resistance. In this study, we designed and synthesized a series of novel CDK4/6 PROTACs based on dalpiciclib incorporating rigid linkers. The optimal compound P11 exhibited potent and selective CDK4/6 degradation activity mediated by the ubiquitin-proteasome system. Binding model analysis demonstrated that P11 is capable of forming a stable CDK6-CRBN-P11 ternary complex. P11 significantly inhibited proliferation and colony formation, and induced cell cycle arrest in breast cancer cell lines. Furthermore, P11 effectively suppressed tumor growth in an MCF-7 xenograft model, demonstrating stronger anti-breast cancer activity than dalpiciclib both in vitro and in vivo. Importantly, P11 showed potential to overcome acquired resistance to CDK4/6 inhibitors. Therefore, P11 could be a promising preclinical candidate for further development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Breast NeoplasmsAntineoplastic AgentsProtein Kinase InhibitorsDrug DiscoveryHumansProteolysis Targeting ChimeraFemaleCell ProliferationAnimalsDrug Screening Assays, AntitumorStructure-Activity RelationshipMolecular StructureMiceDose-Response Relationship, DrugMice, NudeMammary Neoplasms, Experimental

Stichwörter der Autor:innen

CDK4/6Cell cycleDegradationPROTACResistance

Substanzen

Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Proteolysis Targeting ChimeraAntineoplastic AgentsProtein Kinase InhibitorsCDK6 protein, humanCDK4 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines and Jiangsu Provincial Key Laboratory of Targetome and innovative Drugs Medicines, China Pharmaceutical University, Nanjing 211198, China; Department of Medicinal Chemistry, Sch…

Förderung

  • Fundamental Research Funds for the Central Universities
  • Jiangsu Province Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Pan, G., Li, Y., Tan, J., Chen, Y., Chen, W., Yang, H., Zhuang, X., Shen, L., Zong, Z., Fan, Y., Gao, J., Wang, L., Zhang, X. Y., Yang, P., & Yuan, K. (2026). Discovery of rigid linker-based CDK4/6 PROTACs for the treatment of breast cancer. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.110368

Vancouver

Pan G, Li Y, Tan J, Chen Y, Chen W, Yang H, et al. Discovery of rigid linker-based CDK4/6 PROTACs for the treatment of breast cancer. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.110368

BibTeX
@article{Pan2026,
  author = {Pan, Guoyong and Li, You and Tan, Jinke and Chen, Yuanyuan and Chen, Weijiao and Yang, Huanaoyu and Zhuang, Xujie and Shen, Linhu and Zong, Ziyu and Fan, Yiming and Gao, Jiadong and Wang, Liping and Zhang, Xiao-Yu and Yang, Peng and Yuan, Kai},
  title = {Discovery of rigid linker-based CDK4/6 PROTACs for the treatment of breast cancer},
  journal = {Bioorganic Chemistry},
  year = {2026},
  doi = {10.1016/j.bioorg.2026.110368}
}
Kostenlos starten →